Yilin Mao

Background: Atrial fibrillation (AF) is 1 of the most common types of arrhythmias. At present, the treatment for patients with AF mainly includes oral anticoagulants (OACs). Studies have shown that OACs are associated with cognitive decline in patients with atrial fibrillation; however, there is a lack of relevant evidence. This study used Bayesian network meta-analysis (NMA) to investigate the effects of different oral anticoagulants on cognitive decline in patients with AF. Methods: We systematically searched for clinical studies on oral anticoagulants in patients with AF in PubMed, Web of Science, Embase, and the Cochrane Library as of July 3, 2023. Cochrane’s randomized controlled trial bias risk assessment tool and the Newcastle–Ottawa Scale were used to assess the bias risk of the included studies. The main outcome measure was decreased cognitive functioning. Results: Ten studies were included, including 2 RCTs and 7 RCSs, including 882,847 patients with AF. Five oral anticoagulants and 2 anticoagulants were included: VKAs (especially warfarin), Dabigatran, Edoxaban, Rivaroxaban, Apixaban, and Aspirin, Clopidogrel. The results of the mesh meta-analysis showed that VKAs were superior to warfarin in reducing the risk of cognitive decline in patients with AF (OR = −1.19, 95% CI (−2.35, −0.06), P < .05) (Table 5). The top 3 drugs in terms of the probability of reducing the incidence of cognitive impairment in patients with AF with different oral anticoagulants were VKAs (87%), rivaroxaban (62.2%), and dabigatran (60.8%). Conclusion: Based on the results of this study, VKAs may be the best intervention measure for reducing the risk of cognitive decline in patients with AF. Owing to the limitations of this study, more high-quality randomized controlled trials with large sample sizes and multiple centers are required to provide more evidence.

Objective Atrial fibrillation (AF) is one of the most common arrhythmias. At present, the treatment for patients with atrial fibrillation mainly includes oral anticoagulants (OACs). Studies have shown that OACs are associated with cognitive decline in patients with atrial fibrillation, but there is a lack of relevant evidence. This study used Bayesian network meta-analysis to investigate the effects of different oral anticoagulants on cognitive decline in patients with atrial fibrillation. Method We systematically searched the clinical studies of oral anticoagulants on patients with atrial fibrillation included in PubMed, Web of Science, Embase, and Cochrane library as of July 3, 2023. Use Cochrane's randomized controlled trial bias risk assessment tool and Newcastle Ottawa Scale (NOS) to assess the bias risk of the included studies. The main outcome measure was a decrease in cognitive function. Result A total of 10 studies were included, including two RCTs and seven RCSs, including 882847 patients with atrial fibrillation. Including 8 oral anticoagulants: VKAs, Warfarin, Aspirin, Clopidogrel, Dabigatran, Edoxaban, Rivaroxaban, and Apixaban. The results of the mesh meta-analysis showed that VKAs were superior in reducing the risk of cognitive decline in patients with atrial fibrillation compared to warfarin (OR=-1.19, 95% CI (-2.35, -0.06), P < 0.05) (Table 4). The top three in terms of probability of reducing the incidence of cognitive impairment in patients with atrial fibrillation with different oral anticoagulants are VKAs (87%), Rivaroxaban (62.2%), and Dabigatran (60.8%). Conclusion Based on the results of this study, VKAs may be the potential best intervention measures that can reduce the risk of cognitive decline in patients with atrial fibrillation. Due to the limitations of this study, more high-quality randomized controlled trials with large samples and multiple centers are needed in the future to provide more evidence.

Clinical or subclinical cardiotoxicity is a concern for cancer patients receiving anthracycline-based chemotherapy. Carvedilol is promising for preventing anthracycline-induced cardiotoxicity (AIC). This review appraised the preventive effects of carvedilol against AIC based on randomized controlled trials (RCTs).